About 50% of ATLL cases have been shown to have deletions or mutations of the tumor suppressor genes CDK2B (p15), CDKN2A (p16), and TP53 (p53), and this result may guide future treatments [39], [42]. Here, TP53 is linked to adult T-cell leukemia/lymphoma.